FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• FMS-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML) and are associated with poor prognosis.
• FLT3 mutations drive myeloid malignancies, and current treatments like chemotherapy and stem cell transplantation do not overcome this poor prognosis.
• FLT3 inhibitors are highly anticipated for AML treatment, but none are currently approved.

Approach:

• This review summarizes FLT3 inhibitors currently in clinical development.
• It highlights the efficacy and challenges of AC220, a selective FLT3 inhibitor, in Phase I/II trials.
• The review discusses critical issues that need resolution for effective clinical application.

Key Points:

• FLT3 is a type III receptor tyrosine kinase frequently mutated in AML.
• FLT3 mutations are a significant negative prognostic factor in AML.
• AC220 demonstrates potent efficacy against FLT3-mutated AML cells but presents challenges like bone marrow suppression and QTc prolongation.

Conclusions:

• FLT3 inhibitors represent a promising therapeutic strategy for AML.
• Further research is needed to address adverse effects, resistance, and optimal dosing for clinical use.
• Resolving these issues will be critical for the successful clinical application of FLT3 inhibitors in AML treatment.